文献速递心外重症与机械循环支持

左西孟旦输注在接受左心室辅助装置植入患者中的疗效:EUROMACS登记处倾向性评分匹配分析——Euro LEVO-LVAD研究

Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study.
PubMed 文献 · Eur J Cardiothorac Surg · 2023-01-01

基于EUROMACS登记处,比较术前使用左西孟旦与倾向性评分匹配对照组的成人主流连续流左心室辅助装置(LVAD)植入患者。3661例中399例(11%)术前使用左西孟旦,其EUROMACS右心衰评分更高、术后需右心室辅助装置(RVAD)比例更高、ICU停留更长,但右心衰发生率、30天及1年死亡率无显著差异;匹配队列中亦无差异证据。

要点

  • 术前使用左西孟旦者EUROMACS右心衰评分更高:4(2-5.5) vs 2(2-4),P < 0.001。
  • 术前使用左西孟旦者RVAD植入比例更高:32例(8%) vs 178例(5.5%),P = 0.038。
  • 匹配队列中左西孟旦与术后严重右心衰、RVAD植入、ICU停留及30天和1年死亡率无差异证据。

核心结论

  • 在EUROMACS登记处分析中,未发现左西孟旦与早期右心衰或死亡相关的证据,尽管使用左西孟旦者风险特征更高。
  • 作者认为需要多中心随机研究才能得出确定性结论。

研究设计与样本

  • 基于EUROMACS登记处的倾向性评分匹配分析,纳入成人主流连续流LVAD植入患者,比较术前接受左西孟旦治疗者与匹配对照组。

主要发现

  • 共3661例患者接受主流LVAD,其中399例(11%)术前接受左西孟旦治疗。
  • 使用左西孟旦者EUROMACS右心衰评分更高:4(2-5.5) vs 2(2-4),P < 0.001。
  • 使用左西孟旦者RVAD植入更多:32例(8%) vs 178例(5.5%),P = 0.038。
  • 使用左西孟旦者LVAD植入后ICU停留更长:19(8-35) vs 11(5-25),P < 0.001。
  • 右心衰发生率、30天死亡率或1年死亡率无显著差异;匹配队列(357例使用左西孟旦者对比20次插补平均622例对照)中亦未发现术后严重右心衰、RVAD植入率、ICU停留时间或30天和1年死亡率存在差异的证据。

局限性

  • 作者结论指出需要多中心随机研究才能得出确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Early right-sided heart failure (RHF) was seen in 22% of recipients of a left ventricular assist device (LVAD) in the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). However, the optimal treatment of post-LVAD RHF is not well known. Levosimendan has proven to be effective in patients with cardiogenic shock and in those with end-stage heart failure. We sought to evaluate the efficacy of levosimendan on post-LVAD RHF and 30-day and 1-year mortality. METHODS: The EUROMACS Registry was used to identify adults with mainstream continuous-flow LVAD implants who were treated with preoperative levosimendan compared to a propensity matched control cohort. RESULTS: In total, 3661 patients received mainstream LVAD, of which 399 (11%) were treated with levosimendan pre-LVAD. Patients given levosimendan had a higher EUROMACS RHF score [4 (2- 5.5) vs 2 (2- 4); P < 0.001], received more right ventricular assist devices (RVAD) [32 (8%) vs 178 (5.5%); P = 0.038] and stayed longer in the intensive care unit post-LVAD implant [19 (8-35) vs 11(5-25); P < 0.001]. Yet, there was no significant difference in the rate of RHF, 30-day, or 1-year mortality. Also, in the matched cohort (357 patients taking levosimendan compared to an average of 622 controls across 20 imputations), we found no evidence for a difference in postoperative severe RHF, RVAD implant rate, length of stay in the intensive care unit or 30-day and 1-year mortality. CONCLUSIONS: In this analysis of the EUROMACS registry, we found no evidence for an association between levosimendan and early RHF or death, albeit patients taking levosimendan had much higher risk profiles. For a definitive conclusion, a multicentre, randomized study is warranted.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Abdelshafy M, Caliskan K, Simpkin AJ, et al. Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study. Eur J Cardiothorac Surg. 2023. PMID: 36912728. doi:10.1093/ejcts/ezad095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。